December 13, 2020
Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.
December 12, 2020
Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.
December 10, 2020
John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.
November 16, 2020
Robert Weinstock, MD, presents data from a retrospective multicenter study focusing on the efficacy of dexamethasone intraocular suspension 9% delivered at the time of cataract surgery.
November 15, 2020
During AAO 2020, Neal H. Shorstein, MD, explains how physicians at Kaiser Permanente have a streamlined regimen using a prophylactic drop-free drug before cataract surgery for more than a decade.
November 15, 2020
Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.
November 15, 2020
Kristen Brotherson, vice president, US surgical marketing for Alcon, discusses some of the recent advances in cataract surgery-related technologies, including a new advanced lens for patients with presbyopia (AcrySof IQ Vivity IOL).
November 15, 2020
Rudy Nuijts of the University Eye Clinic Maastricht, the Netherlands, discusses the highlights of his AAO 2020 presentation on a combination treatment regimen for lowering the incidence of cystoid macular oedema following category surgery.
November 15, 2020
Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.
November 14, 2020
Ted Leng, MD, MS, Byers Eye Institute at Stanford, and medical advisor for Verana Health, talks about data insights for retinal surgeons. Steven D. Schwartz, MD, Stein Eye Institute, UCLA, highlights his AAO presentation, “New Insight into Real-World U.S. Injection Data."